OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting

Summary by AI BETAClose X

OKYO Pharma announced that its lead candidate, urcosimod, has been accepted for presentation at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, highlighting efficacy and safety data from a proof-of-concept Phase 2 study in neuropathic corneal pain (NCP) patients. This acceptance follows a competitive review and underscores the potential of urcosimod as a novel therapy for NCP, a condition with significant unmet need. The company plans to initiate a 150-patient Phase 2b/3 study in the first half of 2026, building on positive pain reduction signals and encouraging corneal nerve health trends observed in prior studies. Urcosimod has previously received FDA Fast Track designation for NCP.

Disclaimer*

UK 100

Latest directors dealings